

# THE ACADEMY AWARDS, RETINA EDITION



**A**s we write the editorial for this issue, the entertainment community and movie fans anxiously await the 90th Academy Awards. In the spirit of this annual event, we offer you a condensed subspecialty edition, with our predictions for what will be some of the best acts in retina this year.

**Leading Role:** *gene therapy*

The approval of the first gene therapy for patients with an inherited retinal disease in December may be just the thing that opens the door for gene therapy to find a place in the treatment of more common conditions, and for that we nominate this achievement for the leading role in retina 2018.

**Supporting Role:** *drug delivery implants*

Several companies are developing sustained-release implants and formulations that have the potential to deliver medications over months and even years, thereby reducing injection frequency. These devices have the potential to dramatically improve patient satisfaction *and* patient outcomes, which is why we nominate them for their supporting role in the distribution of time-tested therapeutics.

**Cinematography:** *optical coherence tomography angiography (OCTA)*

In the awards world, cinematography refers to the art of making motion pictures, but in retina, it easily translates to the art of ocular imaging. OCTA has garnered quite a bit of interest since its debut, and we continue to see new advances in this technology, allowing us to view more of the retina and more clearly. This is definitely an area we'll continue to watch.

**Special Achievement:** *combination therapies*

Although we can't count on the same treatment regimen to manage every patient with a given condition, combinations of existing and emerging drugs are expanding our options for customized treatment. We are excited to see how these pan out and what new pairings come about.

Do your nominations differ from ours? We welcome your feedback. If you want to see more detailed coverage on a certain topic or from a particular perspective, let us know at [RetinaEditors@bmcrtoday.com](mailto:RetinaEditors@bmcrtoday.com). ■

**ALLEN C. HO, MD**  
CHIEF MEDICAL EDITOR

**ROBERT L. AVERY, MD**  
ASSOCIATE MEDICAL EDITOR

# FOUR FAVORITES

*Retina Today's choice takeaways from this issue.*

**1** "Despite the high incidence of prostate cancer in men, this malignancy maintains an indolent course and rarely metastasizes to the choroid."

**PROSTATE CARCINOMA: COMMON IN MEN BUT RARE IN THE EYE**

*Alexander Graf, BA; Archana Srinivasan, MD; and Carol L. Shields, MD*

Page 27

**2** "DR and DME need not be absolute contraindications to performing cataract surgery when clinically indicated."

**WHEN YOUR DIABETIC PATIENT REQUIRES ANTERIOR SEGMENT ATTENTION**

*Nathan C. Steinle, MD, and Charles C. Wykoff, MD, PhD*

Page 50

**3** "Fellows are exposed to many techniques, but the key to obtaining consistently good results is to know a few techniques very well."

**FOUR-POINT FIXATION FOR SCLERAL-SUTURED IOLS**

*Christopher M. Aderman, MD*

Page 23

**4** "Compared with in-person assessment, a teleophthalmology program serving an isolated First Nations community in Ontario demonstrated significant savings per sight-year and quality-adjusted life year."

**TELEOPHTHALMOLOGY TRAVELS GREAT DISTANCES IN CANADA**

*Parampal S. Grewal, MD; Uriel Rubin, MD; Christopher J. Rudnisky, MD, MPH, FRCSC; and Matthew T.S. Tennant, MD, FRCSC*

Page 18